X4 Pharmaceuticals Inc (XFOR)

$3.80 +0.71 (22.98%)
Market Cap 35.25M
Revenue (ttm) 2.56M
Net Income (ttm) -37.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,462.89%
Debt to Equity Ratio 19.10
Volume 22,119,500
Avg Vol 1,327,784
Day's Range N/A - N/A
Shares Out 11.41M
Stochastic %K 57%
Beta 0.54
Analysts Strong Sell
Price Target $8.70

Company Profile

X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally bioavailable selective antagonist of chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome. The company also develops mavorixafor that is in Phase 3 4WARD clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 529 8300
Address:
61 North Beacon Street, 4th Floor, Boston, United States
Fiona_B
Fiona_B Oct. 25 at 1:47 AM
$EEIQ very interesting dilution-free bottom reversal. There is a .45 to 1.40 nice on the chart if this week's price action continues into next. $XFOR on watch and will spend some time with $CIFR filings this weekend. $DPRO as well!
1 · Reply
dthomps8989
dthomps8989 Oct. 24 at 8:36 PM
$XFOR tutes piling in at 2.90 and my average is 1.60. Life is good
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 4:50 PM
$XFOR not a bad place for a swing idea 💡
0 · Reply
Godwins26
Godwins26 Oct. 24 at 3:31 PM
2nd Watchlist for Bullish 🐃 $YDKG $DVLT $NUAI $NEGG $XFOR
0 · Reply
MrGMac
MrGMac Oct. 24 at 3:05 PM
$XFOR soooo, going to dump soon or what?
0 · Reply
cjwaters14
cjwaters14 Oct. 24 at 2:39 PM
$XFOR is at $3.90 for $100K
0 · Reply
Space_Jam23
Space_Jam23 Oct. 24 at 2:37 PM
$XFOR they type it wrong... suppost to be shelp offering..
0 · Reply
GinoGino
GinoGino Oct. 24 at 2:31 PM
$XFOR I have 01/16/26 $3 call options but no options are trading!
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 2:31 PM
Top Gainers PT2 $QLGN $MOFG $GRND $XFOR $VIOT
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Oct. 24 at 2:23 PM
$XFOR
0 · Reply
Latest News on XFOR
X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

Oct 24, 2025, 12:37 AM EDT - 1 day ago

X4 Pharmaceuticals Announces Pricing of $135 Million Underwritten Public Offering

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

Oct 23, 2025, 4:01 PM EDT - 1 day ago

X4 Pharmaceuticals Announces Proposed Underwritten Public Offering

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

X4 Pharmaceuticals Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 15, 2025, 4:05 PM EDT - 2 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

Aug 13, 2025, 7:00 AM EDT - 2 months ago

X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

Aug 12, 2025, 7:00 AM EDT - 2 months ago

X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

Jun 16, 2025, 8:00 AM EDT - 4 months ago

X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

Jun 10, 2025, 8:00 AM EDT - 4 months ago

X4 Pharmaceuticals Granted Fast Track Designation for Mavorixafor for the Treatment of Chronic Neutropenia by U.S. FDA

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

May 14, 2025, 4:12 PM EDT - 5 months ago

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

May 1, 2025, 12:44 PM EDT - 6 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q1 2025 Earnings Call Transcript

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 1, 2025, 6:01 AM EDT - 6 months ago

X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Top 3 Health Care Stocks That May Rocket Higher In April

Apr 28, 2025, 7:16 AM EDT - 6 months ago

Top 3 Health Care Stocks That May Rocket Higher In April

BMY UNH

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

Apr 24, 2025, 8:03 AM EDT - 6 months ago

X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

X4 Pharmaceuticals Announces Reverse Stock Split

Apr 24, 2025, 8:00 AM EDT - 6 months ago

X4 Pharmaceuticals Announces Reverse Stock Split

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2025, 4:05 PM EDT - 6 months ago

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

Mar 25, 2025, 3:02 PM EDT - 7 months ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 25, 2025, 6:01 AM EDT - 7 months ago

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

Mar 11, 2025, 8:00 AM EDT - 8 months ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

Feb 19, 2025, 7:35 AM EST - 8 months ago

X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

Feb 6, 2025, 7:35 AM EST - 9 months ago

X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

Jan 24, 2025, 7:36 AM EST - 9 months ago

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

Jan 13, 2025, 7:35 AM EST - 10 months ago

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:00 AM EST - 1 year ago

X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 9:31 PM EST - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:07 AM EST - 1 year ago

X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

Nov 13, 2024, 6:01 AM EST - 1 year ago

X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

Oct 24, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 9:30 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q2 2024 Earnings Call Transcript

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Aug 8, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

Jul 2, 2024, 6:17 PM EDT - 1 year ago

X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor Data

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

Jun 27, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

Jun 24, 2024, 4:51 AM EDT - 1 year ago

5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More

MRK NTLA ARWR VRNA

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

May 29, 2024, 4:30 PM EDT - 1 year ago

X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

May 9, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

May 7, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Apr 30, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

Apr 29, 2024, 5:02 PM EDT - 1 year ago

X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

Apr 29, 2024, 6:37 AM EDT - 1 year ago

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

Apr 29, 2024, 6:30 AM EDT - 1 year ago

X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

Apr 1, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 11:35 AM EDT - 1 year ago

X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Mar 21, 2024, 6:01 AM EDT - 1 year ago

X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

Mar 12, 2024, 8:00 AM EDT - 1 year ago

X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

Dec 13, 2023, 11:43 PM EST - 2 years ago

X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth Buying

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

Dec 9, 2023, 12:00 PM EST - 2 years ago

X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

Nov 10, 2023, 8:00 AM EST - 2 years ago

X4 Pharmaceuticals to Participate in Upcoming November Investor Conferences

X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 12:37 PM EST - 2 years ago

X4 Pharmaceuticals, Inc. (XFOR) Q3 2023 Earnings Call Transcript

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Nov 9, 2023, 6:01 AM EST - 2 years ago

X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates

Fiona_B
Fiona_B Oct. 25 at 1:47 AM
$EEIQ very interesting dilution-free bottom reversal. There is a .45 to 1.40 nice on the chart if this week's price action continues into next. $XFOR on watch and will spend some time with $CIFR filings this weekend. $DPRO as well!
1 · Reply
dthomps8989
dthomps8989 Oct. 24 at 8:36 PM
$XFOR tutes piling in at 2.90 and my average is 1.60. Life is good
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 4:50 PM
$XFOR not a bad place for a swing idea 💡
0 · Reply
Godwins26
Godwins26 Oct. 24 at 3:31 PM
2nd Watchlist for Bullish 🐃 $YDKG $DVLT $NUAI $NEGG $XFOR
0 · Reply
MrGMac
MrGMac Oct. 24 at 3:05 PM
$XFOR soooo, going to dump soon or what?
0 · Reply
cjwaters14
cjwaters14 Oct. 24 at 2:39 PM
$XFOR is at $3.90 for $100K
0 · Reply
Space_Jam23
Space_Jam23 Oct. 24 at 2:37 PM
$XFOR they type it wrong... suppost to be shelp offering..
0 · Reply
GinoGino
GinoGino Oct. 24 at 2:31 PM
$XFOR I have 01/16/26 $3 call options but no options are trading!
0 · Reply
topstockalerts
topstockalerts Oct. 24 at 2:31 PM
Top Gainers PT2 $QLGN $MOFG $GRND $XFOR $VIOT
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Oct. 24 at 2:23 PM
$XFOR
0 · Reply
Fremo80
Fremo80 Oct. 24 at 2:22 PM
$XFOR
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 24 at 2:12 PM
$XFOR just turned -6% lower to 20% (~8Mv) moments ago, 11/21 options, follow for more volatility.
0 · Reply
IBOTTheDipAndTheDipWon
IBOTTheDipAndTheDipWon Oct. 24 at 2:12 PM
$XFOR An dilution a day keeps the margin call away.
0 · Reply
The_Fact_ster
The_Fact_ster Oct. 24 at 1:58 PM
$XFOR didn't follow super closely yet, why are we up on a bunch more dilution??
0 · Reply
ChannelRed
ChannelRed Oct. 24 at 1:58 PM
Watching $OPEN $NEUP $XFOR $BYND
0 · Reply
DaBullRunner
DaBullRunner Oct. 24 at 1:52 PM
$WGRX is paying me BIG 💰💰💰 $ZOOZ not resting until I get what I want 🎯✅ $GRND $XFOR $NEUP let’s get it
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 24 at 1:42 PM
$NEUP 11%[68%] $XFOR -8%[21%] $GNLN 7%[-3%] $ETHZ 6%[12%] $CYH 5%[10%] most notable movement within the first minutes of trading.
0 · Reply
Frasier_66
Frasier_66 Oct. 24 at 1:40 PM
$XFOR on hold
0 · Reply
JimBull
JimBull Oct. 24 at 1:40 PM
$XFOR thanks for shorting opportunity !
0 · Reply
jdlman
jdlman Oct. 24 at 1:38 PM
$XFOR nice
0 · Reply
GinoGino
GinoGino Oct. 24 at 1:37 PM
$XFOR the thinking is if investors are paying close to $3 per share to buy millions, they must know something and must expect a very high return on their investment. It’s very good news for longs here.
0 · Reply
Jumabonao
Jumabonao Oct. 24 at 1:34 PM
$XFOR offering!!!! be careful
0 · Reply